McKesson Extends Pharmaceutical Distribution Contract With CVS Through 2032

McKesson shares rose after the company reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032. The deal continues a relationship that has spanned over 25 years, securing a primary revenue stream for the distributor as it maintains its long-term financial targets.

"We are pleased to extend our long-standing, strategic relationship with CVS Health and continue supporting their important role in serving patients and communities across the country," said Brian Tyler, chair and chief executive officer of McKesson.

Scope and Structure of the Agreement

The agreement covers the distribution of pharmaceuticals across the operational footprint of CVS Health, including its mail order, specialty, and retail pharmacy networks, as well as its distribution centers. Although the announcement represents a development for both companies, it is currently an agreement in principle. This status indicates that a final, binding contract has not yet been executed, and the arrangement remains subject to further negotiation before completion.

"For more than 25 years, our teams have worked together to deliver reliable, high-quality services to patients, and we remain committed to building on that strong foundation through our differentiated capabilities and shared focus on improving health outcomes," said Brian Tyler, chair and chief executive officer of McKesson.

Impact on Financial Guidance

Alongside the partnership update, McKesson reaffirmed its fiscal year 2027 adjusted earnings per share (EPS) guidance, projecting a range of $44.20 to $45.00. The company also maintained its long-term adjusted EPS growth rate target of 13% to 16%, indicating operational stability despite the scale of the ongoing CVS contract.

Strategic Importance

For McKesson, the extension of the CVS partnership validates its distribution model. As one of the largest pharmaceutical wholesalers in the United States, McKesson relies on long-term contracts with major pharmacy retailers to maintain volume and supply chain efficiency. The 2032 expiration date provides nearly a decade of visibility into the revenue contribution of the partnership, which is a key metric for institutional investors tracking the long-term growth trajectory of the company.